Multicenter, randomized, placebo- controlled, double blind study of HS219 to evaluate the efficacy and safety in chronic kidney disease patients on hemodialysis with hyperphosphatemia - Study of HS219 in chronic kidney disease patients on hemodialysis with hyperphosphatemia
100 Clinical Results associated with Healthserve Ltd.
0 Patents (Medical) associated with Healthserve Ltd.
100 Deals associated with Healthserve Ltd.
100 Translational Medicine associated with Healthserve Ltd.